Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

MOUNTAIN VIEW, Calif., May 12 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for its fiscal quarter ended March 31, 2008 and provided an update on the Company's progress with its product candidates. The net loss for the 2008 first fiscal quarter, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $14.6 million, compared to a net loss of $10.9 million in the comparable period in 2007. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at March 31, 2008 of $111.7 million.

"The first four months of 2008 have been very productive for Alexza, as we have continued to make progress on all of our product candidates. Importantly, we initiated our first pivotal Phase 3 trial with AZ-004 (Staccato(R) loxapine)," said Thomas B King, President and CEO of Alexza. "We have a comprehensive plan in place to collect the data and other supporting information we will need to submit an NDA for AZ-004. We plan to initiate our second AZ-004 Phase 3 clinical trial in the third quarter of 2008."

Financial Results -- Three Months Ended March 31, 2008 and 2007

GAAP operating expenses were $19.2 million in the first quarter of 2008, compared to $13.8 million for the comparable period in 2007. The first quarter increase resulted from increased spending on AZ-004 and AZ-104 as the Company continued development of these product candidates under the Symphony Allegro agreement, increased spending on AZ-003 with continued development of this product candidate under the development agreement with Endo Pharmaceuticals, increased spending for device development and manufacturi
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
(Date:7/31/2014)... SAN DIEGO and SHENZHEN, China ... Genomics announced today the purchase of an ... genomics organization. BGI selected BioNano,s platform to enable comprehensive ... vastly improved assemblies for various organisms of interest, including ... BGI will partner together to develop new methods for ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Rancho ... the integration of Omicsoft’s Array Suite with tranSMART ... will be able to send data in tranSMART to ... with all versions of tranSMART including the new 1.2 ... statistics, visualization and storage for the analysis of high ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... M2S Expert Dr. Steven Marra will give the ... Sigma in the Imaging Core Lab" at the ... for Clinical Trials conference. Dr. Marra,s presentation will ... principles have contributed to the development of the ...
... -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: PXSL ... Fox,to its senior management team in the position of ... regulatory affairs, pharmacovigilance and,medical affairs. Clinical Operations will ... , Dr Fox has more ...
... journal, Science, reports that advanced cholesterol test aids in ... BIRMINGHAM, Ala., Feb. 16 ... University of Maryland researchers have found an association ... information reported in a recent study could help in ...
Cached Biology Technology:M2S Expert gives address "Applying the Principles of Six Sigma in the Imaging Core Lab" at Imaging for Clinical Trials conference 2Pharmaxis Builds Senior Management Team 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 2VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 3VAP Cholesterol Test Helps In Search For New Heart Disease Drugs 4
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... effect in 1839, humankind has sought to further understand ... purposes. In a new research report published in the ... , scientists may have uncovered a new method ... a naturally occurring combination of lipids that have been ... and across speciessuggests that this specific natural combination of ...
Breaking Biology News(10 mins):Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2Scientists shine bright new light on how living things capture energy from the sun 2
... believes that changes in behaviour among the population have accelerated ... Research published today in Science shows how there has been ... groups, which the researchers attribute to people delaying when they ... found HIV prevalence fell most steeply at young ages, with ...
... venom could provide the next generation of human therapeutic ... been identified by Queensland University of Technology PhD researcher ... vascular surgery and major trauma. , The genetic code ... by PhD researcher Liam St Pierre from QUT's School ...
... a case of evolutionary detective work. Biology researchers at ... have found evidence for an ancient transfer of a ... a bacterium. But the mystery remains as how the ... published this month in the journal Bioinformatics, 22(3): 264-268, ...
Cached Biology News:HIV decline in Zimbabwe linked to behavioural change 2Taipan venom no snake oil 2Evolution mystery: Spider venom and bacteria share same toxin 2
... highly versatile power supply. Capable of producing up ... supply is ideal for PAGE, SDS-PAGE, DNA or ... of small format transfer apparatus. It is designed ... with a continuously variable output in either mode. ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
... a recombinant 177 amino acid polypeptide sequence ... human MT1-MMP. Produced by activation of ... from E. coli periplasm. SPECIFIC ACTIVITY:The ... = 140 mU/mg, where 1 U is ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
Biology Products: